Apollomics Inc Ordinary Shares - Class A APLM 深 滬
等待開盤 07-21 09:30:00 美东时间
6.21
-0.240
-3.72%
華盛通- 最 高6.45
- 今 開6.1524
- 成交量 1.47万股
- 最 低 6.00
- 昨 收 6.45
- 總市值 685.15万
- 52周最高 35.98
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 4.4701
- 委 比 66.67%
- 總股本 110.33万
- 歷史最高 4900.00
- 量 比 1.99
- 振 幅 6.98%
- 歷史最低 4.4701
- 每 手 1
- 風險率 4.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 15.2% to $0.71 durin...
06-14 05:05
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 72.6% to $0.47 during Wedne...
05-22 01:06
Apollomics shares are trading lower. The company reported FY24 financial results.
Apollomics shares are trading lower. The company reported FY24 financial result...
04-05 02:48
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib
Apollomics (NASDAQ:APLM) and LaunXP International, an affiliate of LaunXP Biomedical, announced that the parties have entered into an agreement for the development and commercialization in Asia of veb...
03-31 21:20
(APLM) - Analyzing Apollomics's Short Interest
Apollomics's (NYSE:APLM) short percent of float has risen 16605.56% since its l...
2024-12-04 00:15
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock moved upwards by 26.4% to $...
2024-11-20 05:06
Apollomics stock rallies 30% on Phase 2 vebreltinib data
Apollomics (NASDAQ:APLM) stock rallied 30% in morning trading Tuesday after the company announced positive Phase 2 data for its oncology drug candidate vebreltinib. The preliminary data showed a 43% o...
2024-08-13 22:49
惠誉常青：就中国交通建设(01800.HK)的绿色融资框架出具第二方意见
本文来自微信公众号“惠誉评级”，作者周汉威、何心怡。 7月30日，惠誉常青已就中国交通建设股份有限公司(中国交建)的绿色融资框架出具第二方意见。在该框架下，中国...
2024-07-30 17:24
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-marke...
2024-07-18 18:00
Apollomics Granted 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Requirement
Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers,
2024-07-17 04:50
